Investment will fuel the advancement of its
AI-powered clinical intelligence platform, transforming patient
care and value-based care outcomes
NEW
YORK, March 25, 2025 /PRNewswire/
-- Navina, a market leader in AI-powered clinical
intelligence, today announced the successful completion of a
$55 million Series C funding round,
bringing the total funding to $100
million. The round is led by Growth Equity at Goldman Sachs
Alternatives, with participation from existing investors, including
Vertex Ventures Israel, Grove Ventures and ALIVE.
This significant investment will accelerate Navina's expansion
across the U.S. healthcare market, enhance its proprietary AI
technology, and further drive improvements in patient outcomes by
bringing proactive clinical intelligence to every outpatient
interaction.
"This investment is a powerful validation of Navina's vision to
improve patient outcomes and healthcare economics by breaking down
data barriers with AI," said Ronen
Lavi, co-founder and CEO of Navina. "We're thrilled to
partner with a best-in-class firm like Goldman Sachs, whose market
leadership will be instrumental as we enter this pivotal growth
phase and expand our market reach. With this additional capital, we
will continue to accelerate AI innovation and revolutionize
healthcare by making every patient interaction more empathic,
personalized, and proactive."
Navina's AI copilot has rapidly established itself as the
trusted solution for value-based care organizations, beginning with
primary care and expanding to broader healthcare segments. The
platform serves over 10,000 healthcare professionals across 1,300
clinics and supports the care of more than three million patients.
The company has already secured partnerships with industry leaders
including agilon health, InnovaCare Health, Millennium Physician
Group, and Privia Health, and was recently recognized as Best in
KLAS 2025 for Clinician Digital Workflow, further validating its
exceptional customer satisfaction and trust.
"AI is rapidly transforming modern healthcare, and Navina stands
at the forefront of that transformation – delivering real,
measurable value to thousands of clinicians," said Irit Kahan, Managing Director in Growth Equity
at Goldman Sachs Alternatives. "Their deep integration into
clinical workflows, unparalleled provider trust, and demonstrated
ROI make them uniquely positioned to drive meaningful impact across
the healthcare ecosystem. We believe Navina's AI-powered platform
is a game-changer, and we are excited to support their next stage
of growth."
As healthcare continues to transition toward value-based care,
the need for accurate and timely clinical intelligence has become
more critical than ever. Yet fragmented data, inefficient manual
workflows, and growing administrative burdens make it difficult for
clinicians to deliver proactive, preventive patient care, resulting
in poor clinical outcomes and high cost of care.
Navina equips clinicians and care teams with real-time,
data-driven insights that improve the quality of care and financial
outcomes. Navina's AI copilot surfaces clinical insights that
support effective decision-making throughout the care
continuum–from the back office to the point of care–while
significantly reducing the administrative burden. Navina natively
integrates into the clinician workflow, and maintains an impressive
86% weekly active usage rate and high trust in its AI
recommendations within daily practice.
With this funding, Navina will accelerate the development of its
proprietary AI to ultimately become the definitive source of
unified patient data that improves efficiency and care quality
across the ecosystem from payers to providers. The company will
expand its platform capabilities to further automate and optimize
workflows from proactive population health management to effective
point-of-care intervention.
About Navina
Navina's AI copilot brings clinical intelligence to clinicians
and care teams, transforming care and value-based outcomes.
Navina's powerful AI turns fragmented patient data into a concise
patient profile with actionable insights at every clinical
touchpoint. Designed for and loved by physicians, Navina reduces
missed diagnoses, improves quality metrics and risk adjustment
accuracy, and alleviates the administrative burden—allowing
providers to focus on what matters most: their patients. Privia
Health, agilon health, and Millennium Physician Group are among
some of the leading value-based care organizations leveraging
Navina's AI copilot to enhance clinician workflows and improve
quality performance. The company was selected Best in KLAS 2025 for
Clinician Digital Workflow, and won recognition in the 2024 MedTech
Breakthrough Awards, KLAS Emerging Solutions Top 20 report, and the
CB Insights Digital Health 50 list.
About Growth Equity at Goldman Sachs Alternatives
Goldman Sachs (NYSE: GS) is one of the leading investors in
alternatives globally, with over $500
billion in assets and more than 30 years of experience. The
business invests in the full spectrum of alternatives including
private equity, growth equity, private credit, real estate,
infrastructure, sustainability, and hedge funds. Clients access
these solutions through direct strategies, customized partnerships,
and open-architecture programs.
The business is driven by a focus on partnership and shared
success with its clients, seeking to deliver long-term investment
performance drawing on its global network and deep expertise across
industries and markets.
The alternative investments platform is part of Goldman Sachs
Asset Management, which delivers investment and advisory services
across public and private markets for the world's leading
institutions, financial advisors and individuals. Goldman Sachs has
more than $3.1 trillion in assets
under supervision globally as of December
31, 2024.
Since 2003, Growth Equity at Goldman Sachs Alternatives has
invested over $13 billion in
companies led by visionary founders and CEOs. The team focuses on
investments in growth stage and technology-driven companies
spanning multiple industries, including enterprise technology,
financial technology, consumer and healthcare.
MEDIA CONTACT:
For Goldman Sachs Asset Management
Joseph Stein, +44 207 774 2523
FOR NAVINA:
Brook
Terran
Evergreen & Oak for Navina
336-269-7001
brook@evergreenandoak.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/clinical-ai-leader-navina-secures-55m-series-c-funding-led-by-growth-equity-at-goldman-sachs-alternatives-302410452.html
SOURCE Navina
